therapy for acute myocardial infarction (MI) has been one of the most
potent treatments ever developed for a condition that kills more
patients worldwide than any other. This review will focus on approved
agents and the randomized trials that have led to their widespread use.
The use of adjunctive antithrombotic therapies, such as aspirin and
heparin, also will be discussed, but a more complete discussion of
these therapies is located in other sections of this supplement. A
brief overview of new adjunctive therapies, such as platelet
glycoprotein (GP) IIb/IIIa inhibitors and direct thrombin inhibitors,
will be provided. This section also will explore how therapeutic
success can be evaluated, cost-effectiveness analysis, and
complications with this therapy. Finally, we will provide a set of
recommendations for the use of fibrinolytic therapy in acute MI based
on the published literature.